目的 探討安羅替尼與DP方案（多西他賽+順鉑）聯(lián)合治療晚期非小細(xì)胞肺癌的臨床效果。方法 選擇2018年1月—2021年12月亳州市人民醫(yī)院收治的100例晚期非小細(xì)胞肺癌患者，隨機(jī)分為對(duì)照組和治療組，每組各50例。對(duì)照組給予DP方案化療，每個(gè)周期的第1天靜脈滴注多西他賽注射液，75mg/m²，同時(shí)靜脈滴注順鉑注射液75mg/m²。在對(duì)照組基礎(chǔ)上，治療組口服鹽酸安羅替尼膠囊，12mg/次，1次/d。以21d為1個(gè)周期，兩組均連續(xù)治療4個(gè)周期。觀察兩組患者臨床療效，比較治療前后兩組患者癌癥治療功能評(píng)價(jià)系統(tǒng)-肺癌模塊（FACT-L）評(píng)分和卡氏功能狀態(tài)量表（KPS）評(píng)分，血清鱗狀上皮細(xì)胞癌抗原（SCC）、癌胚抗原（CEA）和細(xì)胞角蛋白片段19（CYFRA21-1）水平，及血管生成調(diào)節(jié)因子血管內(nèi)皮生長因子（VEGF）、內(nèi)皮抑素（ES）和基質(zhì)金屬蛋白酶-9（MMP-9）水平。結(jié)果 治療后，治療組疾病控制率（DCR）比對(duì)照組（84.0%vs70.0%）、客觀緩解率（ORR）比對(duì)照組（68.0%vs52.0%）均顯著升高（P<0.05）。與治療前相比，治療后兩組FACT-L評(píng)分和KPS評(píng)分均顯著升高（P<0.05），且以治療組的升高更顯著（P<0.05）。相比治療前，治療后兩組血清SCC、CEA、CYFRA21-1、VEGF、MMP-9水平均顯著降低，而ES水平則均顯著升高（P<0.05），且均以治療組的改善更顯著（P<0.05）。結(jié)論 安羅替尼與DP方案聯(lián)用治療晚期非小細(xì)胞肺癌能取得較為滿意的療效，可明顯提高患者生存質(zhì)量，降低體內(nèi)腫瘤標(biāo)志物水平，且患者耐受性較好。

Objective To investigate the clinical effect of anlotinib combined with DP regimen in treatment of advanced non-small cell lung cancer. Methods Patients (100 cases) with advanced non-small cell lung cancer in the People’s Hospital of Bozhou from January 2018 to December 2021 were randomly divided into control and treatment group, and each group had 50 cases. Patients in the control group were administered with DP chemotherapy, including intravenous drip of Docetaxel Injection, 75 mg/m², and patients were also iv administered with Cisplatin Injection at the first day per cycle, 75 mg/m². Patients in the treatment group were po administered with Anlotinib Hydrochloride Capsules on the basis of control group, 12 mg/time, once daily. 21 d was one cycle, and they were both treated for 4 cycles of continuous treatment. After treatment, the clinical evaluation was evaluated, the FACT-L score and KPS scores, tumor marker SCC, CEA and CYFRA21-1 levels, the levels of serum angiogenesis regulators VEGF, ES and MMP-9 in two groups before and after treatment were compared. Results After treatment, the disease control rate (DCR) and objective response rate (ORR) of the treatment group were 84.0% and 68.0%, respectively, which were significantly higher than those of the control group (70.0% and 52.0%) (P < 0.05). Compared with before treatment, the FACT-L score and KPS score in two groups after treatment were significantly increased (P < 0.05), and which in the treatment group were higher than that in the control group (P< 0.05). Compared with those before treatment, the serum levels of SCC, CEA, CYFRA21-1, VEGF and MMP-9 were significantly decreased, while the level of ES were significantly increased in two groups after treatment (P < 0.05), and these factors levels in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion The combination of amlotinib and DP regimen can achieve satisfactory anti-tumor effect in the treatment of advanced non-small cell lung cancer, which can significantly improve the quality of life of patients, reduce the level of tumor markers in vivo, and the patients are well tolerated.

R979.1

國家創(chuàng)新藥重點(diǎn)監(jiān)測專項(xiàng)科研基金資助項(xiàng)目（E-2018-32-190033）